Stocklytics Platform
Asset logo for symbol ONCY
Oncolytics Biotech
ONCY44
$0.83arrow_drop_down4.72%-$0.04
Penny Stock
Asset logo for symbol ONCY
ONCY44

$0.83

arrow_drop_down4.72%

Performance History

Chart placeholder
Key Stats
Open$0.87
Prev. Close$0.88
EPS-0.25
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$64.04M
PE Ratio-
LOWHIGH
Day Range0.79
0.88
52 Week Range0.70
2.07
Ratios
Revenue-
EBITDA Margin %-
EPS-0.25

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Oncolytics Biotech (ONCY)

Oncolytics Biotech Inc (ONCY) is a biotechnology company focused on the development of oncolytic viruses for the treatment of various types of cancer. The company's lead product candidate is Pelareorep, a proprietary formulation of the reovirus, which is designed to selectively infect and replicate within cancer cells, causing their destruction. ONCY's unique approach takes advantage of the virus's ability to target and destroy cancer cells while leaving healthy cells unharmed. This targeted therapy has the potential to revolutionize cancer treatment by offering a highly effective and safe alternative to traditional chemotherapy and radiation.
ONCY's stock price history has shown significant volatility over the years. The stock has gone through periods of both strong growth and sharp declines. Investors should be aware of these fluctuations and consider their risk tolerance before investing in ONCY. However, it is important to note that past performance is not indicative of future results, and the stock's price could change significantly in the future.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Matthew C. Coffey M.B.A., Ph.D.
Headquarters
Calgary
Employees
29
Exchange
NASDAQ
add Oncolytics Biotech  to watchlist

Keep an eye on Oncolytics Biotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Oncolytics Biotech 's (ONCY) price per share?

The current price per share for Oncolytics Biotech (ONCY) is $0.83. The stock has seen a price change of -$0.04 recently, indicating a -4.72% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Oncolytics Biotech (ONCY)?

For Oncolytics Biotech (ONCY), the 52-week high is $2.07, which is 149.1% from the current price. The 52-week low is $0.71, the current price is 17.71% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Oncolytics Biotech (ONCY) a growth stock?

Oncolytics Biotech (ONCY) has shown an average price growth of -4.97% over the past three years. It has received a score of 24 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Oncolytics Biotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Oncolytics Biotech (ONCY) stock price performance year to date (YTD)?

As of the latest data, Oncolytics Biotech (ONCY) has a year-to-date price change of -37.05%. Over the past month, the stock has experienced a price change of -15.2%. Over the last three months, the change has been -8.62%. Over the past six months, the figure is -17.72%. Looking at a longer horizon, the five-year price change stands at -52.24%.
help

Is Oncolytics Biotech (ONCY) a profitable company?

Oncolytics Biotech (ONCY) has a net income of -$27.75M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$33.79M. Furthermore, the EBITDA is -$25.36M.
help

What is the market capitalization of Oncolytics Biotech (ONCY)?

Oncolytics Biotech (ONCY) has a market capitalization of $64.05M. The average daily trading volume is 0.85, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level